TrueBinding

We’re excited to share that TrueBinding recently participated in the Precision Medicine World Conference (PMWC) 2025 in Santa Clara, where we showcased our innovative investigational drug TB006 and its potential to transform treatment for Parkinson’s, Adult Autism, and Alzheimer’s disease. With ongoing clinical trials for Parkinson’s and autism, and Phase 2b trials for Alzheimer’s set to begin later this year, we’re proud to be at the forefront of advancing precision medicine. Thank you to everyone who stopped by to learn more about our work—let’s continue driving progress together! #PrecisionMedicine #PMWC2025 #TrueBinding #TB006 #ClinicalTrials #Biotech #Innovation

Excited to attend the SF HealthTech Summit during JPM Healthcare Week! This gathering of innovators and thought leaders highlights the progress we’re making in addressing complex conditions like Alzheimer’s, Parkinson’s, autism, and groundbreaking treatments like TB006. Together, we’re bringing hope to millions of patients and families through groundbreaking research. Let’s continue driving innovation and collaboration to shape the future of healthcare! #HealthTech #Innovation #JPMHealthcare #Alzheimers #Parkinsons #Autism #Hope #FutureOfHealthcare #TB006 #podcast

During the SIC Biotech Symposium at this year’s JPM Conference, we shared exciting progress from TrueBinding as we advance groundbreaking treatments TB006 for Alzheimer’s and Parkinson’s disease. To those impacted by Alzheimer’s, Parkinson’s, and other neurodegenerative conditions: we see you, we hear you, and we are committed to a future where hope becomes reality. #Biotech #Neuroscience #JPM2025 #TrueBinding #Alzheimers #Parkinsons #Hope #SIC

Last week, our team had the privilege of attending the 32nd A4M Anti-Aging Annual World Congress, an incredible gathering of thought leaders and innovators in the field of longevity and brain wellness all over the world. We were thrilled to discuss our investigational drug TB006 with experts and explore its potential to enhance patients' quality of life. Thank you to everyone who visited our booth and joined us for meaningful conversations #A4M #Longevity #Innovation #AgingResearch #QualityOfLife #BrainHealth

Last week, we had the privilege of engaging with leading neurology experts and PhDs to discuss the groundbreaking potential of TB006 as a treatment for Alzheimer's and Parkinson's. Grateful to collaborate with those deeply committed to advancing patient care. We're excited to bring this innovative solution to Singapore soon, offering new hope to patients and families.

TrueBinding has cleared an FDA IND application for TB006 for potential disease modification of Parkinson’s Disease. A multi-center, placebo-controlled, Phase 2A trial of TB006 in the U.S. will be evaluating the safety and efficacy of this treatment in patients with Hoehn and Yahr grade 1 or 2 Parkinson’s Disease. https://lnkd.in/gfT_yHac